Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -158.44% is 46% above its 5-year average of -293.65%, near the high end of its 5-year range (-5865.17%–75.74%).
56.33% below its 12-month average of -101.35%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -54.94%.
EBITDA MARGIN
-158.44%
EBITDA MARGIN AVG TTM
-101.35%
EBITDA MARGIN AVG 3Y
-552.31%
EBITDA MARGIN AVG 5Y
-293.65%
EBITDA MARGIN AVG 10Y
-3032.30%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-56.33%
CURRENT VS 3Y AVG
+71.31%
CURRENT VS 5Y AVG
+46.04%
CURRENT VS 10Y AVG
+94.77%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Syndax Pharmaceuticals, Inc.
Market Cap
$1.54B
EBITDA Margin
-158.44%
TTM Avg
-101.35%
3Y Avg
-552.31%
5Y Avg
-293.65%
Market Cap
$1.52B
EBITDA Margin
33.84%
TTM Avg
32.51%
3Y Avg
-30.03%
5Y Avg
-1.40%
Market Cap
$1.57B
EBITDA Margin
-10.20%
TTM Avg
-140.78%
3Y Avg
-597.36%
5Y Avg
-597.36%
Market Cap
$1.51B
EBITDA Margin
5.15%
TTM Avg
0.72%
3Y Avg
-7.50%
5Y Avg
-11313.48%
Market Cap
$1.49B
EBITDA Margin
16.46%
TTM Avg
14.25%
3Y Avg
12.03%
5Y Avg
12.13%
Market Cap
$1.60B
EBITDA Margin
-1075.09%
TTM Avg
-854.02%
3Y Avg
-886.21%
5Y Avg
-631.69%
Market Cap
$1.61B
EBITDA Margin
-164.52%
TTM Avg
-214.39%
3Y Avg
-473.06%
5Y Avg
-473.06%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Syndax Pharmaceuticals, Inc. (SNDX) | $1.54B | -158.44% | -101.35% | -552.31% | -293.65% |
| Innoviva, Inc. (INVA)vs › | $1.55B | 47.98% | 50.86% | 52.39% | 67.36% |
| Nutex Health, Inc. (NUTX)vs › | $1.52B | 33.84% | 32.51% | -30.03% | -1.40% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | -10.20% | -140.78% | -597.36% | -597.36% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.51B | 5.15% | 0.72% | -7.50% | -11313.48% |
| Phibro Animal Health Corporation (PAHC)vs › | $1.49B | 16.46% | 14.25% | 12.03% | 12.13% |
| uniQure N.V. (QURE)vs › | $1.60B | -1075.09% | -854.02% | -886.21% | -631.69% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.61B | -164.52% | -214.39% | -473.06% | -473.06% |
| Omnicell, Inc. (OMCL)vs › | $1.61B | 8.30% | 8.20% | 7.63% | 9.66% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.47B | N/A | N/A | N/A | N/A |
Gross Margin
97.5%
EBITDA Margin
-158.4%
Operating Margin
-158.4%
Net Margin
-87.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -54.94% |
| 2026-03-31 | -52.72% |
| 2025-12-31 | -91.33% |
| 2025-09-30 | -125.18% |
| 2025-06-30 | -182.56% |
| 2025-03-31 | -372.31% |
| 2024-12-31 | -1254.75% |
| 2024-09-30 | -716.60% |
| 2024-06-30 | -2120.37% |
| 2021-12-31 | 75.74% |
| 2021-09-30 | -161.81% |
| 2021-06-30 | -5865.17% |
| 2021-03-31 | -7136.15% |
| 2020-12-31 | -5220.79% |
| 2020-09-30 | -5232.19% |
| 2020-06-30 | -4376.78% |
| 2020-03-31 | -3978.10% |
| 2019-12-31 | -3620.79% |
| 2019-09-30 | -3456.20% |
| 2019-03-31 | -3860.42% |
| 2018-12-31 | -4992.89% |
| 2018-09-30 | -4669.13% |
| 2018-06-30 | -4980.47% |
| 2018-03-31 | -5194.99% |
| 2017-09-30 | -5013.77% |
| 2017-06-30 | -4514.43% |
| 2017-03-31 | -4318.36% |
| 2016-12-31 | -3619.67% |
| 2016-06-30 | -2829.51% |
| 2016-03-31 | -2852.46% |
| 2015-12-31 | -1530.49% |
| 2015-09-30 | -1858.36% |
| 2015-06-30 | -31594.12% |
| 2014-09-30 | -644.33% |
